Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

This study has been completed.
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Fate Therapeutics Identifier:
First received: April 28, 2009
Last updated: October 7, 2013
Last verified: October 2013